Medical Experiments Exposed copertina

Medical Experiments Exposed

Medical Experiments Exposed

Di: Creator at Obomedia
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
Ever wondered about the strange cures, bizarre medical practices, and shocking experiments from history? Bizarre Medical History uncovers the most unbelievable and often disturbing chapters in the annals of medicine.

Join us for a fascinating exploration into the forgotten corners of medical history, from ancient remedies to the origins of modern surgery, revealing the incredible journeys and sometimes misguided attempts to heal. We delve into the lives of pioneering doctors, the patients who endured their treatments, and the fascinating evolution of healthcare. Discover the surprising origins of common medical terms and the groundbreaking (and sometimes terrifying) discoveries that shaped our understanding of the human body.

New episodes arrive every single day, Monday through Sunday, bright and early at 4:00 AM, offering a daily dose of medical oddities and historical insights. Each episode provides a meticulously researched narrative, perfect for your morning commute or daily routine.

This podcast is for anyone curious about the human body, the history of science, or simply enjoys a well-told story about humanity's quest for health. If you're intrigued by historical medicine, medical curiosities, and the strange path to modern healthcare, this is your ultimate destination.

Subscribe now to Bizarre Medical History and unlock the secrets of the past.© 2026 OBOMEDIA Creators Crimini reali
Episodi
  • He Cut Without Consent: The Australian Surgeon Women Warned About

    He Cut Without Consent: The Australian Surgeon Women Warned About
    Oct 15 2026
    He Cut Without Consent: The Australian Surgeon Women Warned About

    When a routine operation turned into an unexpected clitoridectomy, an ordinary woman woke up missing a body part she never consented to - and her case was only the tip of a crisis spanning nearly two decades. Thirty-five complaints, seventeen criminal charges, and the deaths of ten infants and seven women followed one surgeon’s path through hospitals that repeatedly renewed his access; how did the system let this happen?

    In this episode, we trace the sequence of events, hospital decisions, and missing paperwork that allowed Graeme Stephen Reeves to keep practicing despite formal restrictions, and ask how institutional blindness enabled harm that might have been prevented.

    Person: Graeme Stephen Reeves
    Date: 2002 (Carolyn Dewaegeneire's operation)
    Location: Bega Hospital, New South Wales
    Period: mid-1980s to 2004 (career span covered)
    Case: 35 documented complaints; 17 criminal charges

    - Carolyn Dewaegeneire underwent surgery in 2002 and woke up having had a clitoridectomy without informed consent.
    - Investigators later counted 35 separate complaints lodged against Reeves over fifteen years.
    - Reeves faced 17 criminal charges and was connected to the deaths of 10 infants and 7 women.
    - A Professional Standards Committee in August 1997 explicitly prohibited Reeves from practicing obstetrics.
    - In April 2002, an application to the Greater Southern Area Health Service omitted the 1997 restriction and Reeves was hired without the Medical Board being contacted.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    Mostra di più Mostra meno
    29 min
  • The Molecule That Nearly Became LSD - Silenced by Nausea

    The Molecule That Nearly Became LSD - Silenced by Nausea
    Oct 14 2026
    The Molecule That Nearly Became LSD - Silenced by Nausea

    In this episode, we tell the story of quipazine from its 1966 discovery through human trials and animal experiments, tracing why it was classified as antidepressant-like and then abandoned - and asking whether the nausea problem closed a door science has not yet reopened.

    Person: anonymous human volunteers
    Date: 1966 (first description)
    Compound: quipazine (one-2-quinolinyl-piperazine; “two-QP”)
    Dose: 25 mg oral caused significant gastrointestinal distress
    Receptor profile: potent 5-HT3 agonist; agonist at 5-HT2A/2B/2C; inhibits serotonin reuptake

    - Quipazine was first described in 1966 and later labeled antidepressant-like by 1971.
    - Oral doses of 25 mg in humans produced significant nausea, vomiting, cramping, flatulence and diarrhea.
    - Quipazine is a 1-(2-quinolinyl)-piperazine (also called two-QP) synthesized from 2-chloroquinoline and piperazine.
    - In rodents and monkeys quipazine produced the head-twitch response characteristic of classical psychedelics.
    - In drug discrimination studies, rats fully substituted quipazine for LSD, indicating indistinguishable drug-state effects in that model.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    Mostra di più Mostra meno
    33 min
  • The "(sic)" Dose: How Quipazine Haunted Psychiatry's Psychedelic Moment

    The "(sic)" Dose: How Quipazine Haunted Psychiatry's Psychedelic Moment
    Oct 13 2026
    The "(sic)" Dose: How Quipazine Haunted Psychiatry's Psychedelic Moment

    A tiny notation in a scientific paper - “0.5 mg (sic)” - froze researchers because the number was real and inexplicable, and the compound it described was never meant to be a psychedelic. Quipazine activated both the 5‑HT2A receptor linked to hallucinogens and the 5‑HT3 receptor that causes severe nausea, leaving animal studies screaming psychedelic signals while human trials reported only sickness; how could the same molecule tell such different stories?

    In this episode, we lay out the sequence of experiments, results, and interpretations that turned quipazine into a scientific paradox, from rodent head‑twitches and LSD substitution to primate vomiting and a discontinued 25 mg human trial; can receptor overlap explain why quipazine’s psychedelic promise never reached people?

    Person: James Winter
    Date: 1994
    Dose in publication: 0.5 mg (sic)
    Human trial dose: 25 mg
    Animal result: full substitution for LSD in drug discrimination studies

    - Rodents given quipazine produced a rapid repetitive head‑twitch response matching LSD and mescaline patterns.
    - In drug discrimination experiments rodents trained on LSD could not distinguish quipazine from LSD, indicating full substitution.
    - Monkey trials at psychedelic‑range doses produced projectile vomiting described as severe, linked to 5‑HT3 activation.
    - Human volunteer trial at 25 mg resulted in nausea with no reported LSD‑like subjective effects and was discontinued.
    - James Winter proposed in 1994 that 5‑HT3 receptor activation prevented reaching 5‑HT2A‑mediated effects at tolerable doses.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    Mostra di più Mostra meno
    25 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione